Reddit Posts
How to check if the company you like is going bankrupt! (NXXT, BURU, etc)
$OTLK - Outlook Therapeutics Inc. is Deeply Undervalued
Whenever I sold covered call, it's gonna drop 80% or more 🤷 OTLK
From Pure Momentum To Real Catalysts: Todays Most Discussed Tickers Fall Into 3 Buckets
What's going on with OTLK? Price down day before catalyst.
OTLK — Quick DD: EU launch live, FDA PDUFA Aug 27, and why this catalyst matters
OTLK — Quick DD: EU launch live, FDA PDUFA Aug 27, and why this catalyst matters
OTLK down 80% discounted shares. glta
OTLK - Excellent Investment Opportunity
$OTLK - Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
OTLK - Trenary C Russell III + Dagnon Terry they Bought OTLK Shares on June 21, 2022 (INSIDERS BUY)
OTLK - Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year
OTLK - Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last year
OTLK - Bullish Outlook Therapeutics, Inc. (NASDAQ:OTLK) insiders filled their treasuries with US$557k worth of stock over last yea
OTLK - Interview about confidence in the FDA approval process for BLA
OTLK - JASON HOPE SEC SCHEDULE 13G Number of shares Beneficially Owned on March 18, 2022
OTLK - Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD.
November gainers - top 5 tickers with the highest insiders *buying* activity
November gainers - top tickers with the highest insiders *buying* activity
OTLK - Target Price (in 12 months) +277% to +403%
OTLK - Target Price (in 12 months) +277% to +403%
More Penny Stocks Getting Bought By Insiders - $SELB $OTLK $XOS $PED $HCDI
OTLK - ZACKS give again a BUY recommendations.
Outlook Therapeutics (NASDAQ:OTLK) Lifted to "BUY" at Zacks Investment Research Posted by Joseph Griffin on Aug 26th, 2021
Outlook Therapeutics (NASDAQ:OTLK) Lifted to "BUY" at Zacks Investment Research Posted by Joseph Griffin on Aug 26th, 2021
Outlook Therapeutics (NASDAQ:OTLK) Lifted to "BUY" at Zacks Investment Research Posted by Joseph Griffin on Aug 26th, 2021
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update.
OTLK - Corporate Presentation - August 10, 2021
OTLK 🚀BBIG 🚀VERB 💎there going to the moon
OTLK Price Target Raise to $8,00 (Brookline Capital Markets)
OTLK Positive Efficacy Data on Phase 3 NORSE TWOO
OTLK Potential Buyout above $50 with this Phase 3 Great News
OTLK Today Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™
OTLK Today Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™
Outlook therapeutics(OTLK) report positive efficacy data from Phase 3. Plans to commercialize their product in a $13 billion market
APE Premarket! 08/03 $WHLM $TBIO $OTLK $AUTO $HOLI
APE Premarket! 08/03 $WHLM $TBIO $OTLK $AUTO $HOLI
OTLK Very solid sign for Phase 3 results announcement in Q3 2021
$OTLK Buy and Hold. "BIG PROFITS" on the way!
$OTLK Buy and Hold. "BIG PROFITS" on the way!
$OTLK Chartmill "Outlook Therapeutics Inc is a setup today!"
Interview with C. Russell Trenary III OTLK President and Chief Executive Officer
Interview with C. Russell Trenary III OTLK President and Chief Executive Officer
Something to consider for your portfolios
OTLK-Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer Expert Executive on BLA and M&A
OTLK Outlook Therapeutics is now on Russell 2000® and 3000® Indices.
OTLK Outlook Therapeutics is now on Russell 2000® and 3000® Indices.
OTLK Outlook Therapeutics is now on Russell 2000® and 3000® Indices.
$OTLK Outlook Therapeutics is now on Russell 2000® and 3000® Indices.
OTLK – In June 25, 2021 after market close will be add to Russel 2.000 Index
OTLK will be added to Russell 3000 in JUNE 2021
OTLK - will be added to Russell 3000 in JUNE 2021
OTLK Will Be a Billion Dollar a Year Biotech
BB and the silent assassin OTLK
$OTLK - Outlook Therapeutics - Potential $50 Buyout by EOY/2022 - PT Q3/Q4 2021 is $8 to $12 --- PT Q1/Q2 2022 is $30 to $50 buyout.
$OTLK - Outlook Therapeutics - $50 Buyout Potential EOY, or 2022 - PT Q3/Q4 2021 $8 to $12 -- PT Q1/Q2 2022 $30 to $50
$OTLK Keep Buying and Holding for BIG PROFITS with the next 3 catalyst events:
$OTLK Keep Buying and Holding for BIG PROFITS with the next 3 catalyst events:
OTLK Next 3 big catalyst events for BIG PROFITS
Mentions
OTLK looks like the shorts have had their fun
Still holding OTLK 0.4333 Waiting for the bounce
OTLK should be back over a dollar 50 today with that news, shorts will try and bring it down but I think sense will prevail. Holding for the next week
Might be an unpopular opinion but my PT for OTLK over next few days is 1 or slightly over. It's been volatile with all the volume but the news was significant and puts them back on the track that they were on prior to the dispute.
Loaded up heavy on that OTLK dip too
buying the [OTLK](https://finance.yahoo.com/quote/OTLK/) dip
Of course I stopped out on open for OTLK at 200 loss then jumps back up
https://preview.redd.it/el8cldjmyg3h1.jpeg?width=1014&format=pjpg&auto=webp&s=8fcdf60504ab41676d1ca36248fd7a0dabb0581c OTLK - solid news
I will take the whole show down with my 7 shares of OTLK.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year -HUBC: $920k cash vs $129.5m in current liabilities
Okay, here's what's on my radar for next week, based on filtering and this time, volume: https://preview.redd.it/t0r8eutjb3tg1.png?width=281&format=png&auto=webp&s=d90b93f962927d1f16e6869215531890080d66ea MOBX is definitely a threshold-list frequent flier, but OTLK and KALA haven't logged any entries in quite a while now. Those might be safe to trade now . . . just know that they've been targeted before. If you want me to take a closer look at any of these, just ask.
Me with OTLK in December lmao
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
Y'all are still shilling this one eh? - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
I see what you're saying but OTLK failed to prove drug efficiency while RCKT had a manufacturing issue but they failed twice for the same thing so I don't know how competent they're but that being said they're decreased their workforce by 30% and pulled another drug they were working on to focus on this so maybe........will see im just closely monitoring for now
Ugh getting flashbacks from OTLK. Everyone was saying there's no way it fails FDA approval a fourth time then stock plummets AH. Hopefully RCKT's management is more competent
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
*SCAM ALERT* The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
Here are some examples of commonly posted/pumped stocks will horrendous balance sheets. I anticipate every single one of these companies will massively dilute shareholders within the next 6-12 months in an attempt to stay afloat. I doubt it'll work. NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year - BNZI: $850k cash (+1.83m receivables) vs $26.05m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year - BNAI: $150k cash and receivables vs $12.31m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
Sheesh NUAI I remember that phoney lawsuit bringing NUAI down to the 2s and thought it was undervalued. Then i got caught up with that OTLK hype. Could've doubled my money by now
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill. - HUBC: $920k cash ($19m cash and receivables) vs a hilarious $129.22m in debt/payables due this year
Yup, i said the same thing about RVPH and OTLK and lost 7500USD. Not fun. It is what it is, live and learn.
Yeah same, decided to sell my IBRX and managed to recover my loss from OTLK...don't want to get an stress ulcer with biotech again over a holiday. Even though was tempted to hold...
Just picked up OTLK, at .5479
LMAO more dilutive debt. Ontop of: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert • NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution • BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution • NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution • OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. • MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
I'm not sure what to tell you at this point lol. I will just plug my usual copy+paste. Be careful with holding any of these guys for any meaningful amount of time The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
Yeah, that initial dump when it hit very close to $3 about 7:30 am was the time to get in for a day trade. Congrats on that. Reminds me of the guy on here who bought the OTLK New Years Eve post-market crash at 30 cents and sold minutes later at 45 cents. He would have been even better had he held this the next trading day (Jan 2) when it almost touched 70 cents! Point is -playing the overreeaction to the downside on these small biotechs is a darn profitable play.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
My bags: 1. VSEE - down 51%. Have not averaged down so extra loss 2. OTLK - down 35%. Averaged down; small loss by dollar value 3. ARBE - down 35%. Averaged down. 4. MOBX - down 26%; Averaged down; my most disappointing bag. I genuinely believed in the company. Reasons for hope: 1. Am currently up 35% on my April DPRO $7.50 calls. First purchased Nov. 3, averaged down. Was at one point down a staggering 70%! 2. Currently up 5% on PRZO after being down something like 30%. With $14,000 invested being down 30% hurt.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. - ASBP: $1.95m in cash and $13.86m in debt/payables due this year - SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively I floated by goodwill.
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. -ASBP: $1.95m in cash and $13.86m in debt/payables due this year -SMX: $750k cash vs $22.25 million in debt/payables due this year. Total assets massively inflated by goodwill.
The VP news says to me they re lookign for a buyout, or partnership. Look at that that gals background and the consider the timing of her hire. They are seeking a partnership or buyout from big biotech or pharma. This could involve dilution, or they could instead give up a big chunk of any profits from US sales of the eye drug in exchange for someone else funding whatever the heck it is FDA wants from them. Best case still remains they find out what exactly what it is FDA wants and it turns out to something very minor, like presenting the data in different way, or analyzing it in a different way, and it costs OTLK little time or money to provide what FDA says they want (again).
I know OTLK is possibly circling the drain, but they're up 10% today. Any news other than the new VP of Corporate Strategy?
The Big List of Stupid Balance Sheets. - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and **$32 million current liabilities due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. **Was $41m, but they diluted to pay off debt
REMINDER! The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
There are so many every day that I've genuinely gotten bored of reposting lol The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: *$7m cash and *$30.6 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year. *NRXP recently diluted investors to pay off its debt balance. A very large current liabilities balance still remains.
QNC will probably swing $0.25 down with no news then close flat at $5. Waiting for news before it gets bigger legs and uplisted Hope to ride the OKLO and SLS trains up. Made a good chunk on both today Will grab some SRXH and OTLK cheapies
Good post. As a fellow scam hater, I feel this is an appropriate place to share my Big List of Stupid Balance Sheets: The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
ASBP looks like it's going to dump like OTLK Out
Pretty sure it’ll be after hours, and halts involved. I’m in for a smaller position than what I had on OTLK 🥵
Mine shows I bought the top. OTLK 2.0? 😭
NXXT shills out in full force again today. Don't forget.. The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - impending Bankruptcy Alert - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
The Big List of Stupid Balance Sheets - 2026 - Update 1 - NXXT: $650k cash with $35 million debt/payables due this year and no way to pay beyond dilution - BURU: $6.8m cash with $42 million in debt/payables due this year and no way to pay beyond dilution - NRXP: $7m cash and $41 million debt/payables due this year and no way to pay beyond dilution - OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely. - MNTS: $670k in cash with a whopping $17.3 million in debt/payables due this year.
Glad my OTLK sell didnt go through, slightly clawing back some of my massive loss.
I don’t think I’ll be getting in it again. I doubled down at .35 and sold at .55. Totaled a 19,400 loss… my worst realized loss ever. I had similar with LUNR, but that popped back. I don’t have as much conviction either OTLK
20k shares of OTLK at 1.66.
The bottom would be after a FDA rejection of the drug. Happened to multiple other biotechs lately. Instantly dropped 50% or more. OTLK and RVPH
OTLK for premarket in my opinion on Friday. They don’t have a RS approved, lots of buying volume came in towards the end of AH today. I think we see this to .7
I saw someone on Stocktwits made 300% with puts with a strike price of 0.40 cents on OTLK not sure when they bought them though
I wonder if I could have even bought put options yesterday or today? I bought SLS puts a month ago to hedge there since my position in SL (unlike my OTLK position) is pretty large. Was able to buy SLS puts a month ago no issue, but when I tried at get more SLS puts yesterday it was a no go. SLS is crazily heavily shorted now.
When OTLK dumped to $1.30 or whatever it was premarket, the call option prices didn't dump that much. This gave a false confidence after it was noted that call option prices didn't dump that much with MIST on the last day either. And it was just market manipulation. So that throws the strong option price theory away. I couldn't even buy the call options I wanted. No one was lowering the prices even in the last minutes. People were firm with their option prices. My buy order was ready to go all in. It looks like the news was leaked on both this and CORT also
That's a play for sure. If OTLK gives up on US approval and doesn't try to fund yet another Phase 3, then their cash burn rate will drop dramatically. They still have very little cash on hand though, and UK EU sales aren't going to bring in enough cash, especially during the current ramp up phase (just starting selling there in June). Best case is that after the holidays OTLK can respond to FDA respectfully asking for more details about just what it is they need (and find a way to politely remind them that OTLK just ran another trail giving what they said they wanted!). Best case is FDA comes back with some minor request that is easy for OTLK to meet. Truth is though, FDA is a Federal Gov. regulatory agency. They literally don't have to give OTLK any specifics at all. If they want to keep on saying "We want confirmatory evidence.", without saying exactly what they mean, they can do that and there is nothing OTLK can do.
OTLK now would be a good buy (if your buy order goes through lol), they still have the EU and UK market. Don’t panic sell yet it should get back to the 70s IMO
I doubt it. I'm sure OTLK folks are looking to see if they have any options, but are likely as confused as we are: you got a sense of that in the press release when they noted that FDA "*did not specify what evidence would be acceptable"* OTLK people are like: "WTF!? We did what you wanted and it didn't change a thing!"
OTLK - well I got the dip 0.38x now +45% lol
So OTLK's rejection letter does not read like an outright rejection? More like FDA going back on their own wards? Is there any chance of a reversal?
Anyone else’s market order to sell OTLK taking forever to fill?
I think .30 is the bottom for OTLK, might jump in for a dead cat bounce
Yes it will. 70-90% tankage. Will be below a quarter at least. Was a small play for me, but I'm just so annoyed that FDA didn't even give them a reason. Instead said the same damn thing they said before, as if OTLK didn't just run an additional trial (approved by FDA) to address that.
Glad I went with my gut on OTLK. Told you I had a bad feeling. Dang.
This OTLK drug is already approved in both UK and EU, but the flippin' FDA.... https://preview.redd.it/nrd88to1zlag1.png?width=342&format=png&auto=webp&s=6069a3f1beae8854606c909748a18052010fd17d
It is f---ed up. Last time FDA said they wanted confirmatory evidence. So OTLK designed a trial, got the trial approved by FDA's SPA process, and then ran the trial. They did the damn trail FDA wanted, and FDA still rejects citing the same damn thing they cited last time. Thats one of the drawbacks about biotech investing: FDA can be a crapshoot.
OTLK: Yes, it will tank. They don't have the funds for another trial. Most annying thing is that FDA gave as their reason they had trial that shopwed efficacy, btu they wanted confirmatory evidence. That is totally F---ed up because FDA said the same thing last time and so OTLK got a Phase 3 trial protocol approved by the FDA Special Protocol Assessment Process, then ran that trial. Then FDA comes back after that trial has been run and says the same damn thing they said before!!
OTLK - another CRL, lucky me that I have small amount in it. I have low confidence they will get the approval, just buying in for the ride
How long can this halt on OTLK last?
OTLK received Complete Response letter. **Rejected**.
Not in OTLK but I hope it gets approval and wipes out the shorts
OTLK, FFA non-approval, this ia going to tank
OTLK: https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-provides-regulatory-update-us-food-and-0
OTLK: https://preview.redd.it/81k14xaovlag1.png?width=218&format=png&auto=webp&s=f1ca3e76ff57563d2045a320c938952101807745
Congratulations to everyone that got in on OTLK.
OTLK halted. This is going to the moon.
OTLK approval gonna be AH? Don’t like that
OTLK just gives me a bad feeling. Gonna just sit back and watch what happens. Hoping whoever is holding them gets good news though!
- OTLK: $11m cash and receivables vs $46 million in current debt/payables due this year. No revenue to speak of. Dilution likely.
https://preview.redd.it/49pmgj69glag1.png?width=2028&format=png&auto=webp&s=213d1c659cfcd4a16d3996e32f7324b1c2d3d306 OTLK - waiting for PDUFA outcome, small amount in it and joining the ride.
https://preview.redd.it/dmpvkpclflag1.jpeg?width=208&format=pjpg&auto=webp&s=91e7a16af805bd50d628defb7a3acb18e6cafbfd OTLK - still waiting for PDUFA outcome, small amount in it just for the ride
I feel the MIST vibe too unfortunately. OTLK did not run up prior to PDUFA day though. Expectation is that it is not going to be approved so no pre-announcement run-up. If it tanks will be because it was not approved. If approved it should run as most are not expecting approval.